Off-label use of atypical antipsychotics

November 2011
Travel Medicine Advisor;Nov2011 Supplement, p2
The article focuses on the meta-analysis providing the evidence of efficacy of several atypical antipsychotic drugs for various off-label uses including risperidone, olanzapine, and quetiapine.


Related Articles

  • Ãœberlegungen zur Wirksamkeit von Psychopharmaka. Leucht, S.; Heres, S.; Davis, J. M. // Der Nervenarzt;Nov2011, Vol. 82 Issue 11, p1425 

    Current systematic reviews yielded relatively small efficacy effect sizes of different psychopharmacological agents compared to placebo. It seems that these effect sizes have decreased compared to earlier meta-analyses. We speculate about factors explaining the decrease of effect size such as...

  • Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials. Li, Xianbin; Tang, Yilang; Wang, Chuanyue // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Objective: To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. Methods: Population: adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related...

  • Antipsychotic medication in children rises despite evidence dearth.  // Primary Health Care;Jul2008, Vol. 18 Issue 6, p6 

    The article reports on a meta-analysis study which suggests that typical antipsychotics have no therapeutic advantage but have more side effects than typical antipsychotics. The use of atypical antipsychotics in general practices was investigated in the study. The study claims that prescription...

  • For colored girls.  // Essence (Essence);Sep98, Vol. 29 Issue 5, p56 

    Announces the International Suicide Prevention Trial's search for participants for its study aimed at testing the efficacy of antipsychotic drugs to lower suicide risk.

  • Atypical antipsychotics appear to be effective for only few off-label uses.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p179 

    The article presents information regarding the effectivity of atypical antipsychotic medications indicating that it could only be for a few off-label conditions and that the benefits and harms of these medications for these uses vary.

  • Atypical antipsychotics may aid symptons for some off-label uses, but not others.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p180 

    The article presents study which reveals that the use of atypical antipsychotic medications are only effective in reducing symptoms for some off-label conditions but not with other types of prescriptions.

  • Current Strategies for the Development of Novel Antipsychotic Drugs. J. Bolos // Mini Reviews in Medicinal Chemistry;May2003, Vol. 3 Issue 3, p239 

    While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action...

  • Depot antipsychotics only prescribed if deemed "clearly superior.".  // PharmacoEconomics & Outcomes News;4/3/2010, Issue 600, p5 

    The article discusses research on the effectiveness of depot antipsychotics, by J. Hamann and colleagues, published in the February 2010 issue of "European Neuropsychopharmacology."

  • Off-label use of atypical antipsychotics.  // OB/GYN Clinical Alert;Nov2011 Pharmacology, p2 

    The article reports on a new meta-analysis on the efficacy of several atypical antipsychotics for various off-label uses including risperidone (Risperdal), olanzapine (Zyprexa) and aripiprazole (Abilify) for dementia in elderly people, and quetiapine (Seroquel) for anxiety disorder.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics